[go: up one dir, main page]

CY1116914T1 - ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40 - Google Patents

ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40

Info

Publication number
CY1116914T1
CY1116914T1 CY20151101024T CY151101024T CY1116914T1 CY 1116914 T1 CY1116914 T1 CY 1116914T1 CY 20151101024 T CY20151101024 T CY 20151101024T CY 151101024 T CY151101024 T CY 151101024T CY 1116914 T1 CY1116914 T1 CY 1116914T1
Authority
CY
Cyprus
Prior art keywords
disease
treatment
benzydamine
addicted
benzidamine
Prior art date
Application number
CY20151101024T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Giorgina Mangano
Giuseppe Biondi
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of CY1116914T1 publication Critical patent/CY1116914T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Χρήση βενζυδαμίνης στη θεραπεία φλεγμονωδών ασθενειών, συγκεκριμένα της νόσου του Crohn, της ψωριασικής αρθρίτιδας, και της ψωρίασης, που προκαλούνται από μία έκφραση ή υπερέκφραση της υπομονάδας κυτοκίνης p40.
CY20151101024T 2009-07-08 2015-11-13 ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40 CY1116914T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425270 2009-07-08
EP10728191.7A EP2451452B1 (en) 2009-07-08 2010-06-23 Use of benzydamine in the treatment of p40-dependent diseases

Publications (1)

Publication Number Publication Date
CY1116914T1 true CY1116914T1 (el) 2017-04-05

Family

ID=41279454

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101024T CY1116914T1 (el) 2009-07-08 2015-11-13 ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40

Country Status (25)

Country Link
US (1) US20120302618A1 (el)
EP (1) EP2451452B1 (el)
JP (1) JP5753843B2 (el)
KR (1) KR101723996B1 (el)
CN (1) CN102470125B (el)
AR (1) AR077451A1 (el)
AU (1) AU2010270425B2 (el)
BR (1) BR112012000410B8 (el)
CA (1) CA2760176C (el)
CY (1) CY1116914T1 (el)
DK (1) DK2451452T3 (el)
EA (1) EA022862B1 (el)
ES (1) ES2554332T3 (el)
GE (1) GEP20146156B (el)
HR (1) HRP20151393T8 (el)
HU (1) HUE028220T2 (el)
IL (1) IL216717A (el)
MX (1) MX2012000498A (el)
PL (1) PL2451452T3 (el)
PT (1) PT2451452E (el)
SG (2) SG10201403088XA (el)
SI (1) SI2451452T1 (el)
SM (1) SMT201500277B (el)
UA (1) UA105666C2 (el)
WO (1) WO2011003737A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6698669B2 (ja) * 2015-02-09 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 粘膜炎の治療のための組成物及び方法
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
MX380435B (es) * 2016-07-08 2025-03-12 Acraf Composición farmacéutica que comprende bencidamina.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (el) 1963-08-09
IT1184123B (it) 1985-01-22 1987-10-22 Acraf Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
IT1274026B (it) 1994-03-01 1997-07-14 Acraf Composizione antitosse
IT1274655B (it) 1995-02-28 1997-07-18 Smithkline Beecham Farma Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
ATE462409T1 (de) * 2005-01-14 2010-04-15 Camurus Ab Topische bioadhäsive formulierungen
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
GB0604824D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders

Also Published As

Publication number Publication date
CN102470125B (zh) 2015-08-19
BR112012000410B1 (pt) 2019-12-31
CA2760176A1 (en) 2011-01-13
EA022862B1 (ru) 2016-03-31
EA201270143A1 (ru) 2012-06-29
HK1165280A1 (zh) 2012-11-23
IL216717A0 (en) 2012-02-29
ES2554332T3 (es) 2015-12-18
SI2451452T1 (sl) 2015-12-31
KR101723996B1 (ko) 2017-04-06
BR112012000410B8 (pt) 2020-12-08
DK2451452T3 (en) 2015-11-23
EP2451452B1 (en) 2015-10-07
WO2011003737A1 (en) 2011-01-13
SG10201403088XA (en) 2014-10-30
AR077451A1 (es) 2011-08-31
PL2451452T3 (pl) 2016-03-31
AU2010270425A1 (en) 2011-12-22
BR112012000410A2 (pt) 2016-04-05
KR20120052201A (ko) 2012-05-23
IL216717A (en) 2017-06-29
SG176686A1 (en) 2012-01-30
UA105666C2 (uk) 2014-06-10
CN102470125A (zh) 2012-05-23
GEP20146156B (en) 2014-09-10
JP5753843B2 (ja) 2015-07-22
SMT201500277B (it) 2016-01-08
EP2451452A1 (en) 2012-05-16
CA2760176C (en) 2017-01-03
US20120302618A1 (en) 2012-11-29
JP2012532173A (ja) 2012-12-13
PT2451452E (pt) 2016-01-14
HUE028220T2 (en) 2016-12-28
HRP20151393T1 (hr) 2016-01-15
HRP20151393T8 (hr) 2016-07-01
MX2012000498A (es) 2012-04-30
AU2010270425B2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
MY203509A (en) Il-15 conjugates and uses thereof
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CY1118666T1 (el) Αναστολεις κινασης τυροσινης bruton
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CL2009000447A1 (es) Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
PE20151070A1 (es) Inhibidores de la tirosina - quinasa de bruton
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
TW200732347A (en) VEGF analogs and methods of use
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
UY33219A (es) Cetoenoles cíclicos para terapias
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.